Innovative Targeting Solutions
We are the pioneers of a ground-breaking, next generation protein engineering technology that represents a new paradigm for drug discovery. With our technology, first in class drug discovery is now possible for ANY target, enabling our partners to target the undruggable. Our HuTARG technology is a revolutionary platform for antibody and protein engineering that effectively exploits mammalian display at the scale of billions of unique variants and does not require cloning or transformation of large recombinant libraries, or liquid handling robotics. The platform generates its diversity by using nature’s most powerful diversity generator – V(D)J recombination – to isolate and engineer at the scale of billions directly
Conference Objective
Follow up with existing clients and finding additional partnerships for our novel protein based biologics discovery platform (HuTARG)
Delegate Contacts
Paul has been involved in the development and application of antibody generation technologies for over fourteen years at ImmGenics Pharmaceuticals, Abgenix and Amgen. Paul was one of the original five scientists that left the Biomedical Research Centre at the University of British Columbia to start up ImmGenics in 1998. While at ImmGenics, Paul was part of a team that advanced a novel antibody generation platform called SLAM (Selected Lymphocyte Antibody Method) to identify and isolate very high affinity antibodies (<10pM) from different animal species including humans and rabbits. Shortly after the acquisition of ImmGenics by Abgenix, Paul was one of the lead scientists mandated to apply ImmGenics antibody generation expertise to the XenoMouse technology. The result was a revolutionized and industrialized process that involved improvements to the SLAM technology specifically designed to synergize with the XenoMouse technology. The improved antibody generation technology was subsequently applied successfully to Abgenix and its collaborators’ programs which had previously failed using traditional hybridoma technology. Amgen, after its acquisition of Abgenix, continues to use these methodologies as its sole XenoMouse antibody discovery engine. At Amgen, Paul oversaw Amgen British Columbia’s Preclinical In Vitro Cellular Assay and In Vivo Pharmacology research teams, whose primary responsibilities were the screening and characterization of XenoMouse derived antibodies. Paul was on the steering committee of a number of Abgenix and Amgen collaborations and is an inventor on over fifteen pending or granted patents